Ryffel B
Institute of Pathology, Basel, Switzerland.
Clin Immunol Immunopathol. 1997 Apr;83(1):18-20. doi: 10.1006/clin.1996.4306.
Interleukin 12 (IL-12) activates natural killer and T cells with the secondary synthesis and release of interferon-gamma (IFN-gamma) and therefore enhances a Th1- or cell-mediated immune response. The immunostimulatory property of IL-12 may be used clinically in cancer and viral diseases. Safety studies in rodents and primates demonstrated a rather small therapeutic window with hepato- and splenomegaly, myelodepression, and lung edema. Investigations in mutant mice deficient for the IFN-gamma receptor (IFN-gamma R-/-) revealed that both the biologic and toxic effects are indirect and largely due to IL-12-induced IFN-gamma. The significance of these findings for the safety in man needs to be explored.
白细胞介素12(IL-12)通过干扰素-γ(IFN-γ)的二次合成和释放来激活自然杀伤细胞和T细胞,从而增强Th1或细胞介导的免疫反应。IL-12的免疫刺激特性可在临床用于癌症和病毒性疾病。对啮齿动物和灵长类动物的安全性研究表明,其治疗窗相当窄,会出现肝脾肿大、骨髓抑制和肺水肿。对缺乏干扰素-γ受体(IFN-γR-/-)的突变小鼠的研究表明,其生物学效应和毒性效应都是间接的,且很大程度上归因于IL-12诱导的IFN-γ。这些发现对人类安全性的意义有待探索。